MicrobeWorld App

appsquarebannerad200x200

ASM Fellowships

Fellowship

Microbes After Hours

WaterSupplyYouTubeFrame

Click for more "Microbes After Hours" videos

Join MicrobeWorld

Subscribe via Email

subscribe

Featured Image

Featured Video

Ebola Virus explained

Supporters

ASM House 200X200

ICAAC 2013 - High Dose Therapy for Influenza Drug

Critically ill patients  with the pandemic H1N1 influenza who received triple the standard dose of the influenza drug oseltamivir were 7 times more likely to completely clear the virus from their system in 5 days than those who received the standard dose. This discussion will address the healthcare implications of these findings, including a rationale for high dose therapy of sensitive strains of influenza.

 

Comments (1)

  1. If benefit of the standard dose is minimal, near 0, then 7 times 0 is near 0 too. The BMJ meta-study showed problematic side-effects and a small gain for Tamiflu. Here no side-effects, large gain? Small study, big conclusions? Disclosure: Kumar has a research relationship with Roche Pharmaceuticals. http://www.healio.com/infectious-disease/eacs-2013-resource-center/idn0913kumar_10_3928_1081_597x_20130901_12_1310881 Given two experimental timelines, if you can choose the moment of comparison later at will, there is great chance that there is a cutoff (here after 5 days) when one of the experiments is much better than the other. That would be bad statistics.

Collections (0)

American Society for Microbiology
2012 1752 N Street, N.W. • Washington, DC 20036-2904 • (202) 737-3600
American Society For Microbiology © 2014   |   Privacy Policy   |   Terms of Use